Search Results
Your search for children matches 2089 pages
Showing 1001 - 1050For James Allison, PhD, Perseverance and Hard Science Are Paramount in Cancer Research
For this installment in the Living a Full Life series of articles, guest editor Jame Abraham, MD, interviewed immunology pioneer James Allison, PhD, Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research,...
Closing the Gap in Oncology Care for Adolescents and Young Adults
During her presentation “Adolescent and Young Adult Survivorship: What Do We Still Need to Know?” at the 2017 Cancer Survivorship Symposium: Advancing Care and Research, Emily S. Tonorezos, MD, MPH, a general internist in the Adult Long-Term Follow-Up Program at Memorial Sloan Kettering Cancer...
Molecular Minimal Residual Disease Detection Shows Further Promise in Acute Myeloid Leukemia
Extended next-generation sequencing genomic profiling in acute myeloid leukemia (AML) has revealed remarkable heterogeneity and molecular complexity of the disease and provided critical insights into the genetic mechanisms underpinning of preleukemic and leukemic pathogenesis.1,2 Despite...
Childhood Cancer STAR Act Approved by Senate and House
On May 22, the Childhood Cancer Survivorship Treatment Access and Research (STAR) Act was passed by the Senate and House and is now being sent to President Donald Trump to be signed into law. As the most comprehensive childhood cancer bill ever introduced to Congress, the Childhood Cancer STAR Act...
What to Download and Where to Shop, Dine, and Network at #ASCO18
Network The Conquer Cancer Donor Lounge! (S401) Enjoy light refreshments, computer access, and a quiet place to network with friends and colleagues. Not a donor? Not a problem! Stop by the Donor Lounge between 8:30 AM–5:00 PM or visit CONQUER.ORG/ASCO to make your gift. Shop Pick up a copy of the...
New Leadership Joins Hassenfeld Children’s Hospital at NYU Langone and Perlmutter Cancer Center
Elizabeth A. Raetz, MD, Professor in the Department of Pediatrics at the University of Utah and Primary Children’s Hospital, and Theodore P. Nicolaides, MD, Assistant Professor in the Department of Pediatrics at the University of California, San Francisco, have joined Hassenfeld Children’s...
Treatment Centers Authorized to Administer CAR T-Cell Therapy
The following medical facilities are certified, as of March 2020, to administer the U. S. Food and Drug Administration-approved chimeric antigen receptor (CAR) T-cell therapy: axicabtagene ciloleucel (Yescarta or “A”) for eligible patients with non-Hodgkin lymphoma, and tisagenlecleucel (Kymriah or ...
Weighing the Cost and Value of CAR T-Cell Therapy
This past year’s approval by the U.S. Food and Drug Administration (FDA) of two chimeric antigen receptor (CAR) T-cell therapies heralded a new era in both effective cancer treatments and the most expensive cancer drugs ever. Tisagenlecleucel (Kymriah) was initially approved for the treatment of...
Here’s How ASCO Is Joining With Other Organizations to Reduce Obesity and Cancer Rates
GUEST EDITOR Prevention in Oncology is guest edited by Jennifer A. Ligibel, MD, Chair of ASCO’s Energy Balance Working Group and a member of ASCO’s Cancer Survivorship and Cancer Prevention Committees. Dr. Ligibel is Director of the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber...
New Data on ALK Inhibitors and CAR T-Cell Therapies
The 2018 American Association for Cancer Research (AACR) Annual Meeting was abuzz with more than 22,000 attendees from around the world who came to Chicago to hear the latest in basic science and clinical trial results. Here we present summaries of a few of the highlights from the AACR meeting...
Treating Pediatric Glioma With Bevacizumab and Standard Treatment
Children with nonbrainstem high-grade glioma could benefit from potentially life-extending treatment if genetic testing was used to personalize therapy as it is in many adults, new research published by Mackay et al in Cancer Cell reported. Scientists analyzed the DNA of children taking an...
Upfront Use of Nelarabine Plus Chemotherapy Improves Disease-Free Survival in T-Cell Malignancies
Upfront use of nelarabine plus standard Children’s Oncology Group–augmented Berlin-Frankfurt-Münster (aBFM) chemotherapy boosted survival rates in children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic leukemia (T-LL), according to the...
2018 ASCO: Adding Nelarabine to Standard Chemotherapy Improves Survival in Children and Young Adults With T-Cell Cancers
A large randomized phase III clinical trial by the Children’s Oncology Group (COG) investigating the safety and efficacy of adding nelarabine (Arranon) to COG-augmented Berlin-Frankfurt-Munster chemotherapy (aBFM) to treat newly diagnosed patients with T-cell acute lymphoblastic...
FDA Grants Orphan Drug Designation to CLR 131 in Rhabdomyosarcoma
The U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development recently granted Orphan Drug designation to CLR 131 for the treatment of rhabdomyosarcoma, a rare pediatric cancer. “Rhabdomyosarcoma is the most common type of tissue sarcoma in children. While...
Genetic Counseling and Testing for Patients With Medulloblastoma
Researchers have identified six genes that predispose carriers to develop medulloblastoma and have used the discovery to craft genetic counseling and screening guidelines. The study was published by Waszak et al in The Lancet Oncology. St. Jude Children’s Research Hospital,...
Listen Now to “Remembering Dad”: Latest Release from Your Stories: Conquering Cancer Podcast
HOW DO patients really feel when they are in your care? What does it feel like to cure a cancer? How are the children of oncologists affected when grief is a parent’s occupational hazard? These are the personal topics explored in the candid and inspirational mini-podcast series, Your Stories:...
Parenting Concerns Affect Emotional Well-Being in Mothers With Advanced Cancer
Parenting concerns contributed significantly to the psychological distress of mothers with late-stage cancer, according to a study by University of North Carolina (UNC) Lineberger Comprehensive Cancer Center researchers published by Park et al in the journal Cancer. Cancer is the leading cause of...
Spring
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Infection-Associated Late Mortality in Childhood Cancer Survivors Undergoing Splenectomy or Splenic Radiation
In a report from the Childhood Cancer Survivor Study published in the Journal of Clinical Oncology, Weil et al found that splenectomy and splenic radiation significantly increased the risk of infection-related late mortality among 5-year survivors of childhood cancer. Study Details The study...
Results From AREN0533: Treating Higher-Risk Favorable-Histology Wilms Tumor
In a report from the Children’s Oncology Group AREN0533 study published in Journal of Clinical Oncology, Dix et al found improved survival outcomes with a modified approach to treatment of favorable-histology Wilms tumor with lung metastases. Study Details The National Wilms Tumor Study...
Hematology Fellows and Junior Faculty Participate in 2018 ASH Clinical Research Training Institute in Latin America
This week, the American Society of Hematology (ASH) announced the names of the 35 hematologists participating in the 2018 ASH Clinical Research Training Institute in Latin America (CRTI-LA) and Advanced CRTI-LA. This education and mentorship program was held April 23–26, prior to the...
Cooperative Group Trial Pioneer Dr. James F. Holland Dies at 92
ASCO AND THE ONCOLOGY COMMUNITY are deeply saddened by the loss of James F. Holland, MD, FASCO, who passed away on March 22, 2018. He was 92. Dr. Holland was a Distinguished Professor of Neoplastic Diseases in the Department of Medicine at the Tisch Cancer Institute, Icahn School of Medicine at...
St. Jude Cloud, Largest Public Repository of Pediatric Cancer Genomics Data, Launches for Researchers Worldwide
On April 12, St. Jude Children’s Research Hospital launched the St. Jude Cloud, an online data-sharing and collaboration platform that provides researchers access to the world's largest public repository of pediatric cancer genomics data. Developed as a partnership among St. Jude,...
ASCO Clinical Practice Guideline Update: Fertility Preservation in Patients With Cancer
As reported in the Journal of Clinical Oncology by Kutluk Oktay, MD, PhD, of Yale University School of Medicine, and colleagues, ASCO has issued a clinical practice guideline update on fertility preservation in adults and children with cancer. The update was informed by an update panel systematic...
A Career Based on Service: Both Medical and Military
For this installment in the Living a Full Life series of articles, Edith Peterson Mitchell, MD, was interviewed by Guest Editor Jame Abraham, MD, FACP. Dr. Mitchell is Clinical Professor of Medicine and Medical Oncology in the Division of Medical Oncology at Thomas Jefferson University as well as ...
Enormous Cost of Failure to Screen Heavy Smokers for Lung Nodules
In 2011 the American College of Radiology Imaging Network (ACRIN) group published its publicly funded study of three annual screening chest computed tomography (CT) scans among heavy smokers aged 55 to 74.1 The results remain the first and only screening study for any cancer demonstrating a...
AACR 2018: Crizotinib Yielded a High Objective Response Rate for Adult Patients With ALK-Positive Inflammatory Myofibroblastic Tumor
Among patients with inoperable, advanced, or metastatic ALK-positive inflammatory myofibroblastic tumor, 50% were confirmed to have partial or complete tumor shrinkage after treatment with the ALK-targeted anticancer therapeutic agent crizotinib (Xalkori), according to data from the phase II EORTC...
AACR 2018: Children With Nonchromosomal Birth Defects May Face Higher Risk of Several Childhood Cancers
Children with nonchromosomal birth defects—such as congenital heart disease—had a significantly higher risk of developing childhood cancer than children who did not have birth defects, according to a study presented at the 2018 American Association for Cancer Research (AACR) Annual...
Larotrectinib in Pediatric Solid Tumors With TRK Gene Fusions
As reported in The Lancet Oncology by Laetsch et al, phase I results from an ongoing phase I/II trial have shown activity of the TRK kinase inhibitor larotrectinib in pediatric patients with solid tumors harboring TRK fusions. Study Details In the study, 24 patients in a dose-escalation cohort...
Conquer Cancer Foundation Sparks Global Oncology Innovation and Partnerships With IIG and IDEA Awards
ASCO’s Conquer Cancer Foundation has announced the recipients of its 2018 International Innovation Grants (IIG) and International Development and Education Awards (IDEA). Both the grant and award support oncology professionals in low-and middle-income countries, investing in either an innovative...
Greater Understanding of Family Dynamics May Help Cancer Teams Guide, Support Patients
WHETHER THEY are parents themselves or dealing with their own parents, patients with cancer often look to their health-care team to help guide these relationships, but data on how best to help are lacking, according to two poster presentations at the 2018 American Psychosocial Oncology Society...
Undefeated
I’m sure every cancer survivor feels this way, but my diagnosis, in 1997, of stage III germ cell testicular cancer couldn’t have come at a worse time in my life. I was nearing the end of a 60-city tour with my figure skating show Stars on Ice, when a nagging pain in my abdomen became so severe I...
FDA Expands Approval of Blinatumomab for Certain Patients With B-Cell Precursor ALL
The U.S. Food and Drug Administration granted accelerated approval to blinatumomab (Blincyto) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). In patients who have achieved remission after...
SGO 2018: Gender Differences May Play a Role in Lack of HPV Vaccination
Parents are less likely to vaccinate adolescent boys than girls with the human papillomavirus (HPV) vaccine, and they are twice as likely to report their main reason as a lack of provider recommendation, according to a study presented at the 2018 Society of Gynecologic Oncology (SGO) Annual Meeting ...
Baylor Receives $3 Million to Fund Grants in Tobacco Control, Cancer Screening, and Cancer Treatments
RESEARCHERS AT Baylor College of Medicine have received more than $3 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund three new grants focused on tobacco control, cancer screening, and novel treatments for cancer in children and adults. CPRIT was launched in 2009...
Conquer Cancer Podcast Series Goes Unscripted With Doctors, Patients, and Caregivers
How do patients really feel when they are in your care? What does it feel like to cure cancer? How are the children of oncologists affected when grief is a parent’s occupational hazard? These are the personal topics explored in the candid and inspirational mini-podcast series Your Stories:...
ASCO International: 2017 Year in Review
In late 2016, ASCO announced further expansion of its robust portfolio of international programs, and significant progress toward this expansion was achieved in 2017. All of these accomplishments reflect the hard work and commitment of many ASCO member volunteers, ASCO staff, and organizations...
Ashwagandha
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present information on...
ASCO Names CAR T-Cell Immunotherapy Its Clinical Advance of the Year
This past January, ASCO published Clinical Cancer Advances 2018,1 its 13th annual report on the progress being made against cancer. The report names chimeric antigen receptor (CAR) T-cell immunotherapy as ASCO’s Advance of the Year. In 2017, the U.S. Food and Drug Administration (FDA) approved two ...
AACR 2018: Prior Chemotherapies May Impair Pediatric Patients’ Ability to Develop Effective CAR T Cells
Pediatric patients with solid tumors may have poor quality T cells compared to patients with leukemia, and certain chemotherapies were detrimental to the T cells and their potential to become chimeric antigen receptor (CAR) T cells, according to data presented during a media preview for the...
Many AYA Cancer Survivors Have More Social Connections Than Peers With No History of Cancer
Survivors of adolescent and young adult (AYA) cancer often have stronger social networks than their peers with no cancer history, according to St. Jude Children’s Research Hospital researchers, who hope to translate that support into better health outcomes for the nation’s...
A River Runs Through the Life of a Leukemia Specialist
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. MATT KALAYCIO, MD Affiliation: Cleveland Clinic Taussig Cancer InstituteOn balancing priorities: “As an oncologist in...
Seeking Beauty From the Inside Out After Cancer Treatment
BOOKMARK Title: Autobiography of a FaceAuthor: Lucy GrealyPublisher: Houghton Mifflin HarcourtOriginal Publication Date: June 1994Price: $14.95, paperback; 256 pages We live in a celebrity-obsessed society that is consumed by images of what we perceive as ideal beauty. Numerous studies show that ...
Dasatinib for Pediatric Chronic Myeloid Leukemia in Chronic Phase
As reported in the Journal of Clinical Oncology by Gore et al, a phase II trial has shown high response rates with dasatinib treatment in pediatric patients with Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP). Findings in the trial supported the...
Proud to Be a Pioneer in CAR T-Cell Therapy
Six years ago, I was 38 years old and, like many young people, took life for granted. I had two young daughters, ages 7 years and 4 months, and a wife I adored. And, except for a nagging pain on the left side of my abdomen, I was blessed with good health. Then, suddenly, the pain became so...
Study Uses Music Medicine to Reduce Stress in Pediatric Patients
In a first-of-its-kind collaboration, the Children’s Cancer Association, Randall Children’s Hospital at Legacy Emanuel, and Legacy Research Institute, of Portland, Oregon, co-led a study to assess the impact of using live music as medicine on postoperative pediatric patients to reduce pain and...
Adolescent and Young Adult Cancer Survivors Often Struggle With Reproductive and Sexual Health Concerns
FOR MANY adolescents and young adults (AYAs), the most distressing and troubling phase of the cancer continuum that began with diagnosis is survivorship, and among the toughest challenges are those involving sexual health and reproduction, Jessica Gorman, PhD, MPH, stated at the 11th Annual...
Called to Lead: Tara O. Henderson, MD, MPH, Selected for Presidential Leadership Scholars Program
ASCO congratulates pediatric oncologist Tara O. Henderson, MD, MPH, on being selected for the 2018 Presidential Leadership Scholars (PLS) program. This highly competitive and prestigious national program was created to help individuals from many professional backgrounds develop the practical...
Alex Huang, MD, PhD, Receives $450,000 From Pediatric Cancer Research Foundation
Cancer researcher Alex Huang MD, PhD, has received a $450,000 Basic Science grant from the Pediatric Cancer Research Foundation to study targeted approaches for effectively eliminating metastatic osteosarcoma. Dr. Huang is Professor of Pediatrics at Case Western Reserve University School of...
Genomic Analyses Highlight Need for Precision Therapies That Target Pediatric Cancers
Researchers have determined that children and adults with cancer often have different mutated genes driving their disease, which suggests they would likely benefit from different therapies. The finding, from a collaborative study led by St. Jude Children’s Research Hospital and published by...
